Granite Investment Partners’s CareDx CDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-435,178
Closed -$16.1M 266
2022
Q1
$16.1M Sell
435,178
-39,744
-8% -$1.55M 0.55% 75
2021
Q4
$21.6M Buy
474,922
+18,258
+4% +$953K 0.63% 63
2021
Q3
$28.9M Sell
456,664
-13,019
-3% -$991K 0.9% 34
2021
Q2
$43M Buy
469,683
+409
+0.1% +$32.5K 1.32% 11
2021
Q1
$32M Sell
469,274
-17,144
-4% -$1.33M 1.06% 22
2020
Q4
$35.2M Sell
486,418
-273,819
-36% -$15.9M 1.23% 12
2020
Q3
$28.8M Sell
760,237
-19,597
-3% -$662K 1.28% 12
2020
Q2
$27.6M Buy
779,834
+4,137
+0.5% +$118K 1.33% 12
2020
Q1
$16.9M Buy
+775,697
New +$17.4M 1.1% 21

Other funds holding CDNA

Granite Investment Partners's CDNA Position: Q2 2022 in Review

Granite Investment Partners sold out of CareDx (CDNA) in Q2 2022, closing a stake of 435,178 shares — an estimated $16.1M sold.

Granite Investment Partners first reported a position in CDNA in Q1 2020 and held it in 9 quarters. The position peaked at $43M in Q2 2021. 184 funds tracked by Wall St. Rank hold CDNA as of Q2 2022.

  • Granite Investment Partners reported no remaining CareDx position as of Q2 2022 after selling out during the quarter.
  • Granite Investment Partners sold 435,178 CareDx shares in Q2 2022, an estimated $16.1M.
  • Granite Investment Partners first reported a position in CareDx in Q1 2020 and held it in 9 quarters.
  • Granite Investment Partners's CareDx position peaked at $43M in Q2 2021.
  • 184 funds tracked by Wall St. Rank held CareDx as of Q2 2022.

Based on Granite Investment Partners's 13F filing for Q2 2022, filed 22 Jul 2022.